Cancer Supportive Care Products Market Report 2024

This Cancer Supportive Care Products industry report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The cancer supportive care products market size has grown steadily in recent years. It will grow from $20.58 billion in 2023 to $21.56 billion in 2024 at a compound annual growth rate (CAGR) of 4.8%. The growth during the historic period can be attributed to the rising incidence of cancer, increased awareness and education, enhancements in healthcare infrastructure, a growing geriatric population, and advancements in early detection.

The cancer supportive care products market size is expected to see steady growth in the next few years. It will grow to $26.1 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The anticipated growth during the forecast period can be attributed to the increasing prevalence of cancer, a shift toward patient-centric approaches, growing investment in cancer research, a rising focus on personalized medicine, and improved cancer survival rates. Key trends expected include technological advancements, advanced drug delivery systems, new drug formulations, personalized care, and the development of biodegradable products.

The growing incidence of cancer is expected to drive the expansion of the cancer supportive care products market in the future. As populations age, the risk of cancer increases due to cellular changes and prolonged exposure to various risk factors. Additionally, lifestyle factors such as smoking, poor diet, insufficient physical activity, and excessive alcohol consumption contribute significantly to cancer risk. Cancer supportive care products are designed to manage symptoms, enhance quality of life, and support patients undergoing treatment, addressing the increasing need due to the rising cancer rates. For example, in January 2024, the American Cancer Society, a US-based non-profit organization focused on cancer elimination, projected 58,450 cases of oral cavity and pharynx cancer, marking a 7.2% increase from the 54,540 cases reported in 2023. Consequently, the rising incidence of cancer is expected to propel the growth of the cancer supportive care products market.

Leading companies in the cancer supportive care products market are working on innovations such as targeted radioligand therapy (RLT) platforms to improve treatment effectiveness, reduce side effects, and enhance patient outcomes. RLT platforms use radiolabeled molecules that specifically bind to cancer cell markers to deliver targeted radiation, destroying cancer cells while preserving healthy tissue. For instance, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company, received FDA approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has not responded to previous treatments. Pluvicto is the first FDA-approved targeted radioligand therapy for this condition, combining a targeting ligand with a therapeutic radioisotope. Additionally, the FDA approved Locametz (gallium Ga 68 gozetotide injection), used in PET scans to detect PSMA-positive lesions, aiding in the identification of cancer spread and determining suitability for Pluvicto treatment.

In October 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired POINT Biopharma Global Inc. for an undisclosed sum. This acquisition aims to enhance Eli Lilly's capabilities in targeted radiopharmaceuticals for cancer treatment. POINT Biopharma Global Inc., a US-based biotechnology company, focuses on developing and commercializing radiopharmaceuticals for targeted cancer therapies.

Major companies operating in the cancer supportive care products market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Becton Dickinson and Company, Teva Pharmaceutical Industries Limited, Baxter International Inc., Daiichi Sankyo Company Limited, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Kyowa Hakko Kirin Co. Ltd., QIAGEN N.V., Exelixis Inc., Fagron Group B.V., Tessa Therapeutics Pte Ltd., Mirati Therapeutics Inc., APR Applied Pharma Science Research S.A., Acacia Pharma Ltd., Arquer Diagnostics Ltd.

North America was the largest region in the cancer supportive care products market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer supportive care products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer supportive care products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cancer supportive care products encompass a range of medical treatments, therapies, and products designed to manage and alleviate the symptoms, side effects, and complications associated with cancer and its treatments. These products aim to enhance the quality of life for cancer patients by providing physical, emotional, and psychological support.

Key categories of drugs in cancer supportive care include nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infective drugs, anti-emetics, monoclonal antibodies, erythropoietin-stimulating agents, opioid analgesics, bisphosphonates, and granulocyte colony-stimulating factors. NSAIDs, for example, help reduce inflammation, pain, and fever by inhibiting enzymes involved in the inflammatory process, which assists in managing pain and discomfort related to cancer and its treatments. These products are used for various types of cancer, including lung, breast, prostate, liver, bladder, leukemia, ovarian, and melanoma cancers. They are distributed through hospital pharmacies, retail pharmacies, and compounding pharmacies.

The cancer supportive care products market research report is one of a series of new reports that provides cancer supportive care products market statistics, including cancer supportive care products industry global market size, regional shares, competitors with an cancer supportive care products market share, detailed cancer supportive care products market segments, market trends and opportunities, and any further data you may need to thrive in the cancer supportive care products industry. This cancer supportive care products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer supportive care products market consists of sales of medications, nutritional supplements, pain management products, and therapeutic devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.